Makers Laboratories Limited Share Price

Equities

MAKERSL6

INE987A01010

Pharmaceuticals

Market Closed - Bombay S.E. 08:00:41 18/05/2024 BST 5-day change 1st Jan Change
145 INR 0.00% Intraday chart for Makers Laboratories Limited +5.34% +4.58%

Financials

Sales 2022 1.28B 15.42M 1.21B Sales 2023 1.01B 12.17M 957M Capitalization 576M 6.92M 544M
Net income 2022 49M 589K 46.31M Net income 2023 -47M -565K -44.42M EV / Sales 2022 0.79 x
Net Debt 2022 112M 1.35M 106M Net Debt 2023 94.83M 1.14M 89.62M EV / Sales 2023 0.66 x
P/E ratio 2022
18 x
P/E ratio 2023
-12.4 x
Employees 121
Yield 2022 *
-
Yield 2023
-
Free-Float 34.94%
More Fundamentals * Assessed data
Dynamic Chart
Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024 CI
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Makers Laboratories Gets Eurasian Economic Union RU GMP Certificate for Ophthalmic Eye Drops Manufacturing Plant MT
Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Makers Laboratories Limited Appoints Surbhi Sharma as Company Secretary and Compliance Officer CI
CARE Affirms BBB+ Rating on Makers Laboratories' Bank Financing; Outlook Stable MT
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Makers Laboratories Limited Announces Resignation of Rinku Kholakiya as Company Secretary CI
Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Makers Laboratories Limited Appoints Rinku Kholakiya as the Company Secretary, Compliance Officer CI
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
More news
1 week+5.34%
Current month+2.47%
1 month+6.46%
3 months+1.61%
6 months+31.77%
Current year+4.58%
More quotes
1 week
133.80
Extreme 133.8
144.95
1 month
130.55
Extreme 130.55
155.00
Current year
108.40
Extreme 108.4
155.00
1 year
94.00
Extreme 94
157.00
3 years
94.00
Extreme 94
252.00
5 years
23.20
Extreme 23.2
344.80
10 years
16.50
Extreme 16.5
344.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 30/06/96
Director of Finance/CFO 57 25/12/96
Sales & Marketing 52 01/08/17
Members of the board TitleAgeSince
Director of Finance/CFO 76 28/04/09
Chairman 75 12/02/19
Chief Executive Officer 49 30/06/96
More insiders
Date Price Change Volume
18/05/24 145 0.00% 39
17/05/24 145 +1.90% 2,469
16/05/24 142.2 +0.78% 3,967
15/05/24 141.2 +2.47% 4,954
14/05/24 137.8 -1.61% 3,507

Delayed Quote Bombay S.E., May 18, 2024 at 08:00 am

More quotes
Makers Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceuticals. The Company operates through the pharmaceuticals segment. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range) and Exylin (Amoxycillin range). Its Inspira retail packs division includes acid regulatory (PPIS), anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensives, and others. Its Experia bulk packs division includes amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and others.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. MAKERSL6 Stock